This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease.
Yuji Oba, MD
Advertisement
Articles by Yuji Oba, MD
Continuous home oxygen therapy for chronic obstructive pulmonary disease seems more cost-effective than other health technologies covered by Medicare, while nocturnal oxygen therapy is not.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
5